FDA Accepts Supplemental NDA for Argatroban in Sodium Chloride
The FDA has accepted a supplemental NDA for Argatroban in Sodium Chloride submitted by Eugia Pharma.
Asset / Drug
Drug and asset intelligence for Argatroban with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.